Severity: Warning
Message: fopen(/var/lib/php/sessions/ci_session74uutk458hi1tepf9m6qkkh836pj9km4): Failed to open stream: No space left on device
Filename: drivers/Session_files_driver.php
Line Number: 177
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
Severity: Warning
Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)
Filename: Session/Session.php
Line Number: 137
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
67 results match your criteria: "Institute for Myeloma and Bone Cancer Research[Affiliation]"
Case Rep Oncol
July 2024
Berenson Cancer Center, West Hollywood, CA, USA.
Introduction: Multiple myeloma (MM) is an incurable bone marrow (BM)-based cancer involving clonal plasma cells. Most patients show elevated levels of serum monoclonal protein (sMP) and kappa or lambda serum free light chains (sFLCs) at diagnosis. However, around 1-2% of patients, termed nonsecretory, do not produce these biomarkers.
View Article and Find Full Text PDFOncotarget
February 2024
ONCOtherapeutics, West Hollywood, CA 90069, USA.
Multiple myeloma (MM) is the most common primary malignancy of the bone marrow. No established curative treatment is currently available for patients diagnosed with MM. In recent years, new and more effective drugs have become available for the treatment of this B-cell malignancy.
View Article and Find Full Text PDFTarget Oncol
September 2023
Institute for Myeloma and Bone Cancer Research, Suite 300, 9201 W. Sunset Boulevard, West Hollywood, CA, 90069, USA.
Background: Progression-free survival (PFS) and overall survival (OS) of newly diagnosed multiple myeloma (MM) patients have been widely published in the clinical trials setting, but data published from real-world settings are limited.
Objective: We determined the survival and factors that predict outcomes among 161 unselected, newly diagnosed MM patients whose frontline therapy was started at a single clinic specializing in the treatment of this B-cell malignancy.
Patients And Methods: None of these patients underwent an autologous stem cell transplantation as part of their initial therapy and the population had a high proportion (35%) of cytogenetic high-risk patients.
Clin Adv Hematol Oncol
September 2023
ONCOtherapeutics, West Hollywood, California.
Multiple myeloma (MM) is a clonal plasma cell dyscrasia and the most common form of primary bone marrow cancer. Nearly 35,000 new cases of MM are diagnosed in the United States each year. MM is a slowly progressive illness that remains incurable.
View Article and Find Full Text PDFEur J Haematol
October 2023
Berenson Cancer Center, West Hollywood, California, USA.
Objectives: Isatuximab is approved for treatment of relapsed/refractory multiple myeloma (RRMM) with dexamethasone and carfilzomib or pomalidomide. Patients receiving these three-drug regimens have exhibited more Grade ≥ 3 adverse events (AEs) compared to the two-drug class combination of isatuximab and steroids alone. Thus, this single-center retrospective study investigated the efficacy of isatuximab with dexamethasone and methylprednisolone (ISAdm) for RRMM patients showing only biochemical progression (BP) of their disease.
View Article and Find Full Text PDFCancer Rep (Hoboken)
May 2023
Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA.
Background: Multiple myeloma (MM) patients have variable responses to mRNA vaccination to COVID-19. Little is known regarding their vaccine-induced antibody levels over time.
Methods: We monitored spike IgG antibody levels over 24 weeks among a subset of 18 MM patients who showed a full response after two mRNA vaccinations.
Clin Infect Pract
January 2023
Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, United States.
We have reported that IgG antibody responses following two mRNA COVID-19 vaccinations are impaired among patients with multiple myeloma (MM). In the current study, sixty-seven patients with MM were tested for anti-spike IgG antibodies 0-60 days prior to their first vaccination, 14-28 days following the second dose, and both before and 14-28 days after their third dose of the mRNA-1273 or BNT162b2 vaccines. After the first two doses, most patients' (93 %) antibody levels declined to ineffective levels (<250 BAU/mL) prior to their third dose (D3).
View Article and Find Full Text PDFBr J Haematol
March 2023
Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, California, USA.
Although Janus kinase (JAK) inhibitors have demonstrated efficacy for treating autoimmune disorders and myeloproliferative neoplasms, their efficacy in treating other types of cancer has not been clearly demonstrated. We evaluated oral ruxolitinib (15 mg twice daily) with oral methylprednisolone (40 mg every other day) for multiple myeloma (MM) patients with progressive disease who had received a proteasome inhibitor, lenalidomide, glucocorticosteroids and three or more prior regimens. All of the planned 29 patients had been enrolled with follow-up until 28 April 2022.
View Article and Find Full Text PDFEur J Haematol
February 2023
Berenson Cancer Center, West Hollywood, California, USA.
Hematol Oncol
December 2022
Cedars-Sinai Medical Center, Los Angeles, California, USA.
Ruxolitinib with lenalidomide and dexamethasone shows anti-myeloma effects in vitro and in vivo. MUC1 leads to lenalidomide resistance in multiple myeloma (MM) cells, and ruxolitinib blocks its expression. Thus, ruxolitinib may restore sensitivity to lenalidomide.
View Article and Find Full Text PDFExp Hematol
October 2022
Berenson Cancer Center, West Hollywood, CA; Oncotherapeutics, West Hollywood, CA; Institute for Myeloma and Bone Cancer Research, West Hollywood, CA. Electronic address:
Exp Hematol
July 2022
OncoTracker Inc., West Hollywood, CA; Oncotherapeutics, West Hollywood, CA; Institute for Myeloma and Bone Cancer Research, West Hollywood, CA. Electronic address:
B-Cell maturation antigen (BCMA) is a cell membrane receptor expressed on mature B lymphocytes, with elevated serum levels found among patients with B-cell malignancies, including chronic lymphocytic leukemia (CLL). Serum BCMA (sBCMA) levels were measured in 331 untreated, newly diagnosed CLL patients using an enzyme-linked immunosorbent assay with a polyclonal anti-BCMA antibody. Elevated sBCMA levels were found among patients with CLL compared with age- and sex-matched healthy controls and those with more active CLL based on prognostic factors.
View Article and Find Full Text PDFHematol Oncol
April 2022
James R. Berenson, MD, Inc., West Hollywood, California, USA.
Previous retrospective studies have shown that serum B-cell maturation antigen (sBCMA) levels predict outcomes among patients with multiple myeloma (MM) undergoing new treatments. Specifically, baseline levels and changes during treatment of this protein predict both progression free survival (PFS) and overall survival. However, prospective studies are lacking evaluating sBCMA for determining outcomes among MM patients undergoing new treatments.
View Article and Find Full Text PDFClin Infect Pract
January 2022
Institute for Myeloma and Bone Cancer Research, 9201 Sunset Blvd #300, West Hollywood, CA 90069, USA.
Background: Patients with multiple myeloma have unpredictable responses to vaccination for COVID-19. Anti-spike antibody levels can determine which patients develop antibodies at levels similar to healthy controls, and are a known correlate of protection.
Case Report: A multiple myeloma patient developed protective anti-spike antibodies after vaccination (608 IU/mL), but nonetheless developed severe breakthrough COVID-19 just 10 weeks following his second vaccination with mRNA-1273.
Leukemia
December 2021
Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA.
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response against SARS-CoV-2 is unknown. Thus, we analyzed responses to mRNA vaccination against COVID-19 among these patients.
View Article and Find Full Text PDFTarget Oncol
July 2021
Institute for Myeloma and Bone Cancer Research, 9201 W. Sunset Blvd., Ste. 300, West Hollywood, CA, 90069, USA.
Background: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells from patients with multiple myeloma (MM). These patients have higher levels of serum (s)BCMA than healthy subjects, and levels correlate with disease status. The half-life of sBCMA is only 24-36 h, and levels are independent of renal function.
View Article and Find Full Text PDFEur J Haematol
September 2021
Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA.
Multiple myeloma (MM) patients with smoldering (S) disease are defined by a lack of CRAB/SLiM criteria but may transform into disease requiring treatment. The International Myeloma Working Group risk stratification model for SMM uses serum M-protein, serum-free light chain ratio, and bone marrow plasma cell percentage. We investigated whether baseline serum B-cell maturation antigen (sBCMA) levels are predictive of disease progression among 65 patients with SMM.
View Article and Find Full Text PDFBr J Haematol
February 2021
Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA.
Clin Lymphoma Myeloma Leuk
November 2020
James R. Berenson, MD, Inc, West Hollywood, CA; Oncotherapeutics, West Hollywood, CA; Institute for Myeloma and Bone Cancer Research, West Hollywood, CA. Electronic address:
Clin Lymphoma Myeloma Leuk
August 2020
James R. Berenson MD, Inc, West Hollywood, CA; Oncotherapeutics, West Hollywood, CA; Institute for Myeloma and Bone Cancer Research, West Hollywood, CA. Electronic address:
Clin Cancer Res
May 2020
Cedars-Sinai Medical Center, Los Angeles, California.
Purpose: Ruxolitinib with lenalidomide and dexamethasone shows antimyeloma effects and . MUC1 leads to lenalidomide resistance in multiple myeloma cells, and ruxolitinib blocks its expression. Thus, ruxolitinib may restore sensitivity to lenalidomide.
View Article and Find Full Text PDFTarget Oncol
October 2019
Institute for Myeloma and Bone Cancer Research, 9201 Sunset Boulevard, Suite 300, West Hollywood, CA, 90069, USA.
Background: Chronic lymphocytic leukemia (CLL) is a malignancy of late B cells. In another late B-cell malignancy (multiple myeloma), levels of solubilized B-cell maturation antigen (sBCMA) are elevated and predict outcomes.
Objective: We sought to evaluate sBCMA as a possible prognostic factor and monitoring tool for patients with CLL.
J Allergy Clin Immunol Pract
January 2020
Division of Clinical Immunology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:
Background: Primary antibody deficiencies (PADs) are the most prevalent primary immunodeficiencies. More severe forms of PADs-common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA)-require immunoglobulin replacement therapy (IRT) and may have serious complications. Differentiating severe PAD from milder hypogammaglobulinemia not requiring IRT can involve prolonged evaluations and treatment discontinuation.
View Article and Find Full Text PDFClin Lymphoma Myeloma Leuk
September 2019
Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY.
Introduction: This phase Ib study evaluated oprozomib, an oral proteasome inhibitor, plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma (RRMM).
Patients And Methods: Patients received oprozomib once-daily on days 1 to 5 and 15 to 19 (5/14 schedule; 150 mg/day starting dose) or on 2 consecutive days weekly (2/7 schedule; 210 mg/day starting dose) of 28-day cycles, pomalidomide on days 1 to 21 (4 mg/day starting dose), and dexamethasone 20 mg on 2 consecutive days weekly. A 3 + 3 dose-escalation schema was used to determine the maximum tolerated dose.
Clin Lymphoma Myeloma Leuk
September 2018
James R. Berenson, MD, Inc, West Hollywood, CA; Institute for Myeloma and Bone Cancer Research, West Hollywood, CA; Oncotherapeutics, West Hollywood, CA. Electronic address: